Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTP1 | P09211 | 1/20 | 0.41 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | PRNP | P04156 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.35 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 5/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28447462 | 0.86 | ALDH1A1 (0.41) | KMT2APRNPPOLBRXFP1ALDH1A1 | |
| SCHEMBL29506152 | 0.77 | GSTP1 (0.38) | GSTP1GSTM2KMT2APRNPPOLB | |
| SCHEMBL21855863 | 0.77 | GSTP1 (0.38) | GSTP1GSTM2KMT2APRNPPOLB | |
| SCHEMBL29506065 | 0.73 | GSTP1 (0.43) | GSTP1GSTM2KMT2APRNPPOLB | |
| SCHEMBL21855732 | 0.73 | GSTP1 (0.43) | GSTP1GSTM2KMT2APRNPPOLB | |
| SCHEMBL18319841 | 0.72 | KMT2A (0.45) | GSTP1GSTM2KMT2APRNPPOLB | |
| SCHEMBL29506060 | 0.72 | KMT2A (0.45) | GSTP1GSTM2KMT2APRNPPOLB | |
| SCHEMBL24388764 | 0.72 | ALDH1A1 (0.35) | ALDH1A1CYP1A2 | |
| SCHEMBL21852192 | 0.71 | GSTP1 (0.42) | GSTP1GSTM2KMT2APRNPPOLB | |
| SCHEMBL18320486 | 0.71 | KMT2A (0.44) | GSTP1GSTM2KMT2APRNPPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441743-B2 | Spiro aromatic ring compound and use thereof | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2025-10-14 | — | — | US | disclosed |
| US-20240116949-A1 | SPIRO AROMATIC RING COMPOUND AND USE THEREOF | ETERN BIOPHARMA SHANGHAI CO LTD (CN) | 2024-04-11 | — | — | US | disclosed |
| US-11685748-B2 | Spiro aromatic ring compound and application thereof | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2023-06-27 | — | — | US | disclosed |
| US-11685748-B2 | Spiro aromatic ring compound and application thereof | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2023-06-27 | — | — | US | disclosed |
| US-11685748-B2 | Spiro aromatic ring compound and application thereof | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2023-06-27 | — | — | US | disclosed |
| EP-3712151-B1 | (S)-1'-(8-((2-AMINO-3-CHLOROPYRIDIN-4-YL)THIO)IMIDAZO[1,2-C]PYRIMIDIN-5-YL)-5,7-DIHYDROSPIRO[CYCLOPENTA[B]PYRIDINE-6,4'-PIPERIDINE]-5-AMINE AS SHP2 INHIBITOR FOR THE TREATMENT OF CANCER | ETERN BIOPHARMA SHANGHAI CO LTD (CN) | 2022-03-02 | — | — | EP | disclosed |
| US-20210238196-A1 | SPIRO AROMATIC RING COMPOUND AND APPLICATION THEREOF | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2021-08-05 | — | — | US | disclosed |
| US-20210238196-A1 | SPIRO AROMATIC RING COMPOUND AND APPLICATION THEREOF | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2021-08-05 | — | — | US | disclosed |
| US-10844079-B2 | Spiro aromatic ring compound and application thereof | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2020-11-24 | — | — | US | disclosed |
| US-10844079-B2 | Spiro aromatic ring compound and application thereof | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2020-11-24 | — | — | US | disclosed |
| US-20200317695-A1 | SPIRO AROMATIC RING COMPOUND AND APPLICATION THEREOF | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2020-10-08 | — | — | US | disclosed |
| US-20200317695-A1 | SPIRO AROMATIC RING COMPOUND AND APPLICATION THEREOF | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2020-10-08 | — | — | US | disclosed |
| EP-3712151-A1 | SPIRO AROMATIC RING COMPOUND AND APPLICATION THEREOF | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2020-09-23 | — | — | EP | disclosed |
| EP-3712151-A1 | SPIRO AROMATIC RING COMPOUND AND APPLICATION THEREOF | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2020-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238196-A1 | SPIRO AROMATIC RING COMPOUND AND APPLICATION THEREOF | PTPN1, PTPN5, PTPN2 | GSTP1 751/4885GSTM2 1522/4885KMT2A 2424/4885 |
| US-20240116949-A1 | SPIRO AROMATIC RING COMPOUND AND USE THEREOF | PTPN1, PTPN11, PTPN5 | GSTP1 996/4885GSTM2 2042/4885KMT2A 2455/4885 |
| US-12441743-B2 | Spiro aromatic ring compound and use thereof | PTPN1, PTPN11, PTPN5 | GSTP1 996/4885GSTM2 2042/4885KMT2A 2455/4885 |
| US-10844079-B2 | Spiro aromatic ring compound and application thereof | PTPN1, PTPN11, PTPN5 | GSTP1 1175/4885GSTM2 2157/4885KMT2A 2397/4885 |
| US-20200317695-A1 | SPIRO AROMATIC RING COMPOUND AND APPLICATION THEREOF | PTPN1, PTPN11, PTPN5 | GSTP1 1175/4885GSTM2 2157/4885KMT2A 2397/4885 |
| US-11685748-B2 | Spiro aromatic ring compound and application thereof | PTPN1, PTPN11, PTPN5 | GSTP1 1175/4885GSTM2 2157/4885KMT2A 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.